Abstract
The rising antibiotic drug resistance is a worldwide issue and has various challenges in new antibiotic drug development. The present study came up with a solution for drug resistance to one the most used antibiotics such as moxifloxacin (Moxi) by supramolecular chemistry. Moxi is a fourth-generation fluoroquinolone drug widely used in respiratory infections. It was encapsulated with p-Sulfontocalix[6]arene (SCX6) and characterized in order to improve its solubility, antibacterial activity and safety. This inclusion complex (M⊂SCX6) was investigated by spectroscopic techniques such as UV–visible, Fluorescence, FT-IR, FE-SEM, HRMS and NMR spectroscopy. The antibacterial study of M⊂SCX6 was evaluated against pathogens S. aureus and E. coli. While, the cytotoxicity study on 3T3-L1 mouse embryonic-fibroblast cell lines and Human RBCs has evaluated the safety of complex M⊂SCX6. Overall, the present study has suggested a novel drug complex with better antibiotic activity and possible therapeutic advantages for tackling antibiotic drug resistance in new drug doses form M⊂SCX6.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
